Could the mosaic pattern of chromosomal abnormality predict overall survival of patients with myelodysplastic syndrome?
Küçük Resim Yok
Tarih
2016
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
King Faisal Specialist Hospital and Research Centre
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective/background Myelodysplastic syndromes (MDSs) are a group of monoclonal hematopoietic diseases consisting of a number of various entities. The presence of differences in chromosomal content of cells within the same individual is known as chromosomal mosaicism. The impact of mosaic pattern on the prognosis of MDS has been unclear. In this study, we aimed to determine the impact of mosaic pattern on the survival of patients with MDS. Methods We retrospectively evaluated 119 patients diagnosed with MDS at the Trakya University Faculty of Medicine, Department of Hematology. Giemsa-Trypsin-Giemsa banding was used to evaluate chromosomal abnormality. The effect of chromosomal abnormality mosaicism on overall survival and transformation to acute leukemia was evaluated by Kaplan-Meier survival analysis. Results The mean age at diagnosis was 66.3 years, and the mean disease duration was 24.2 months. Chromosomal abnormality was observed in 32.5% of patients. Patients with chromosomal abnormalities comprising at least 50% metaphases had significantly lower overall survival than patients with abnormality comprising up to 50% of all abnormal metaphases (p =.003). There were no differences in transformation to acute leukemia among patients with higher and lower chromosomal mosaicism (p =.056). Conclusion The most important outcome of this study was to demonstrate worse overall survival rates in MDS patients with higher abnormal chromosomal mosaicism than patients with lesser abnormal chromosomal mosaicism. Higher levels of abnormal chromosomal mosaicism did not predict transformation to acute leukemia. The cause of worse outcomes of patients with higher abnormal chromosomal mosaicism may be related to clonal mass. © 2016 King Faisal Specialist Hospital & Research Centre.Published by Elsevier Ltd.
Açıklama
Anahtar Kelimeler
Chromosomal Abnormality; Mosaicism; Myelodysplastic Syndrome; Prognosis, Antineoplastic Agent; Eltrombopag; Erythropoietin; Hypomethylating Agent; Iron Chelating Agent; Thalidomide; Trypsin; Unclassified Drug; Acute Leukemia; Aged; Article; Blood Transfusion; Breast Carcinoma; Cancer Mortality; Cancer Radiotherapy; Chromosome Aberration; Chromosome Banding Pattern; Clonal Variation; Controlled Study; Disease Association; Disease Classification; Disease Duration; Female; Genetic Transformation; Giemsa Stain; Hodgkin Disease; Human; Kaplan Meier Method; Major Clinical Study; Male; Malignant Transformation; Metaphase; Mosaicism; Multivariate Analysis; Myelodysplastic Syndrome; Overall Survival; Palliative Therapy; Retrospective Study; Very Elderly; Adult; Chromosome Aberration; Demography; Genetics; Karyotyping; Middle Aged; Mosaicism; Myelodysplastic Syndrome; Pathology; Survival Analysis; World Health Organization; Adult; Aged; Aged, 80 And Over; Chromosome Aberrations; Demography; Female; Humans; Karyotyping; Male; Metaphase; Middle Aged; Mosaicism; Myelodysplastic Syndromes; Survival Analysis; World Health Organization
Kaynak
Hematology/ Oncology and Stem Cell Therapy
WoS Q Değeri
Scopus Q Değeri
Q2
Cilt
9
Sayı
2
